Latest Share Chat

REMOVE ADS

Glaxosmithkline Regulatory News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes

Get Live Data

1,851.50 31.00 (1.70%)

Bid:

1,851.50

Ask:

1,852.00

Spread: 0.50 (0.027%)

Market Cap: £74.25b

Last checked at -

Intraday Glaxosmithkline Share Chart

REMOVE ADS

Director/PDMR Shareholding - Replacement

13 Feb 2024 16:45

RNS Number : 0202D

GSK PLC

13 February 2024

GSK plc (the 'Company')

Correction - ?Vesting of Performance Share Plan Awards

This notification sets out the vesting details of awards over Ordinary Shares and American Depositary Shares ('ADSs') made to Persons Discharging Managerial Responsibilities ('PDMRs') and their Persons Closely Associated ('PCAs') in February 2021 under the GlaxoSmithKline 2017 Performance Share Plan ('PSP'), which were subject to relevant business performance conditions, and the subsequent sale of ordinary shares and ADSs to meet tax liabilities. Awards were made in 2021 and the three-year performance period commenced on 1 January 2021 and ended on 31 December 2023. The vested shares for the Executive Directors are now subject to an additional two-year vesting period.

The performance measure vesting details for those PDMRs who received awards in 2021 are set out in the following table.

		Outcome and Vesting Level
Portion of the Award	Measure and Outcome	% of maximum	% of award
30%	Adjusted Free Cash Flow - For the three years ending 31 December 2023, the Company achieved Adjusted Free Cash Flow calculated in accordance with the principles for the measure of £9.81bn, which is above the revised amount of £6.54bn required for maximum vesting. Adjustments to the original target and vesting schedule were set out in detail in the 2022 Annual Report.	100	30.00
30%	Total Shareholder Return - For the three-year period the Company's Total Shareholder Return ranked 9th, which is below the threshold vesting level against a comparator group of 10 global pharmaceutical companies including GSK.	0	0.00
20%	Innovation Sales - For the three-year period, the Company achieved revenues from new products calculated in accordance with the principles for the measure of £18.651bn, which is slightly below the level of £18.667bn required for 100% vesting. The threshold vesting level was £15.273bn.	99.77	19.95
20%	Pipeline Progress - measure is equally weighted between: - Pivotal trial starts - Major regulatory approvals	100 100	10.00 10.00
	Total vesting for 2021 award Lapsed	69.95 30.05	69.95

The notifications that follow are for awards made to PDMRs and their PCAs and detail the PSP conditional awards that vested, including dividends accrued, on 9 February 2024. The balance of the award made to each PDMR and PCA has lapsed.

The closing prices of Ordinary Shares and of ADSs of GSK plc on the vesting date were £16.60 and $41.91.

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Emma Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary Shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan. These shares are now subject to a two-year hold.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	441,309

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	89,414

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.6055	47,864

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	139,077

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.6055	65,367

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Sally Jackson
b)	Position/status	SVP, Global Communications and CEO Office
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	52,746

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Sally Jackson
b)	Position/status	SVP, Global Communications and CEO Office
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.6055	24,791

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dylan Jackson
b)	Position/status	PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021, 2022 and 2023 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	7,642

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dylan Jackson
b)	Position/status	PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021, 2022 and 2023 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.6055	3,592

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Luke Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	195,810

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Luke Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.6055	13,864

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Shobie Ramakrishnan
b)	Position/status	Chief Digital and Technology Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	The number of ADSs vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$0.00	5,383

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Shobie Ramakrishnan
b)	Position/status	Chief Digital and Technology Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	The sale of ADSs to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$41.84	2,894

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	161,385

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.6055	75,851

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	133,024

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.6055	62,522

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Phil Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	73,728

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Phil Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.6055	34,653

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, GSK Global Health
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	94,120

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, GSK Global Health
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.6055	44,237

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary Shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	24,473

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary Shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.6055	11,503

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Victoria Whyte
b)	Position/status	Company Secretary
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The number of Ordinary Shares vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	9,456

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Victoria Whyte
b)	Position/status	Company Secretary
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.6055	4,445

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	The number of ADSs vesting on awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$0.00	107,377

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044
b)	Nature of the transaction	The sale of ADSs to meet tax liabilities for the vesting of awards granted in 2021 under the Company's 2017 Performance Share Plan
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$41.84	57,716

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2024-02-09
f)	Place of the transaction	New York Stock Exchange (XNYS)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHZZGMZVFFGDZM

Date		Source	Headline
10th Mar 2025	7:00 am	RNS	Transaction in Own Shares
7th Mar 2025	7:00 am	RNS	Transaction in Own Shares
6th Mar 2025	7:00 am	RNS	Transaction in Own Shares
5th Mar 2025	7:00 am	RNS	Transaction in Own Shares
4th Mar 2025	7:00 am	RNS	Transaction in Own Shares
3rd Mar 2025	5:15 pm	RNS	GSK plc 2024 Annual Report on Form 20-F
3rd Mar 2025	3:00 pm	RNS	Total Voting Rights
3rd Mar 2025	7:05 am	RNS	US FDA accept 2 depemokimab indication submissions
3rd Mar 2025	7:00 am	RNS	ANCHOR results presented at 2025 AAAAI
3rd Mar 2025	7:00 am	RNS	Transaction in Own Shares
28th Feb 2025	7:00 am	RNS	Transaction in Own Shares
27th Feb 2025	10:00 am	RNS	GSK publishes Annual Report 2024
27th Feb 2025	7:00 am	RNS	Transaction in Own Shares
26th Feb 2025	4:00 pm	RNS	Director/PDMR Shareholding
26th Feb 2025	7:00 am	RNS	Transaction in Own Shares
25th Feb 2025	7:00 am	RNS	Transaction in Own Shares
24th Feb 2025	7:05 am	RNS	GSK completes acquisition of IDRx, Inc.
24th Feb 2025	7:00 am	RNS	GSK plc commences share buyback programme
21st Feb 2025	7:00 am	RNS	Directorate Change
21st Feb 2025	7:00 am	RNS	Director/PDMR Shareholding
21st Feb 2025	7:00 am	RNS	Director/PDMR Shareholding
21st Feb 2025	7:00 am	RNS	Director/PDMR Shareholding
21st Feb 2025	7:00 am	RNS	Director/PDMR Shareholding
21st Feb 2025	7:00 am	RNS	Director/PDMR Shareholding
21st Feb 2025	7:00 am	RNS	Director/PDMR Shareholding
20th Feb 2025	7:00 am	RNS	Nucala COPD submission accepted in China
17th Feb 2025	7:00 am	RNS	GSK 5-in-1 meningitis vaccine approved by US FDA
13th Feb 2025	3:30 pm	RNS	Director/PDMR Shareholding
11th Feb 2025	3:30 pm	RNS	Director/PDMR Shareholding
5th Feb 2025	7:00 am	RNS	Final Results
3rd Feb 2025	4:48 pm	RNS	Total Voting Rights
28th Jan 2025	7:05 am	RNS	Depemokimab dual filing in China and Japan
28th Jan 2025	7:00 am	RNS	EMA accepts two submissions for depemokimab
27th Jan 2025	7:05 am	RNS	EMA accept review Shingrix syringe presentation
20th Jan 2025	7:00 am	RNS	Jemperli expanded approval in the EU
16th Jan 2025	3:30 pm	RNS	Director/PDMR Shareholding
15th Jan 2025	3:30 pm	RNS	Director/PDMR Shareholding
14th Jan 2025	3:30 pm	RNS	Director/PDMR Shareholding
13th Jan 2025	3:30 pm	RNS	Director/PDMR Shareholding
13th Jan 2025	7:00 am	RNS	GSK enters agreement to acquire IDRx, Inc.
10th Jan 2025	7:00 am	RNS	Shingrix fully liquid accepted for US FDA review
7th Jan 2025	7:00 am	RNS	GSK ADC gets FDA breakthrough therapy designation
3rd Jan 2025	7:00 am	RNS	GSK’s Nucala approved in China for use in CRSwNP
2nd Jan 2025	3:00 pm	RNS	Total Voting Rights
23rd Dec 2024	3:30 pm	RNS	Director/PDMR Shareholding
20th Dec 2024	9:00 am	RNS	Block Listing Application
20th Dec 2024	7:00 am	RNS	Headline results from phase III FIRST trial
16th Dec 2024	7:11 am	RNS	Jemperli receives US FDA breakthrough designation
16th Dec 2024	7:05 am	RNS	EMA grants PRIME Designation for GSK’227
16th Dec 2024	7:00 am	RNS	Jemperli receives positive CHMP opinion

Latest Share Chat

Glaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding - Replacement

Please enter at least 2 characters

No results found

Search results

Recently viewed

Trending